Acadian Asset Management LLC Has $9.06 Million Stock Position in Kodiak Sciences Inc. (NASDAQ:KOD)

Acadian Asset Management LLC cut its holdings in Kodiak Sciences Inc. (NASDAQ:KOD) by 9.7% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,722,890 shares of the company’s stock after selling 185,412 shares during the quarter. Acadian Asset Management LLC’s holdings in Kodiak Sciences were worth $9,059,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. JGP Global Gestao de Recursos Ltda. acquired a new position in shares of Kodiak Sciences during the fourth quarter valued at about $46,000. Diversified Trust Co acquired a new position in Kodiak Sciences during the 1st quarter worth approximately $83,000. Marquette Asset Management LLC boosted its holdings in Kodiak Sciences by 58.5% in the fourth quarter. Marquette Asset Management LLC now owns 47,944 shares of the company’s stock worth $146,000 after acquiring an additional 17,686 shares in the last quarter. Strs Ohio boosted its holdings in Kodiak Sciences by 400.0% in the fourth quarter. Strs Ohio now owns 34,000 shares of the company’s stock worth $103,000 after acquiring an additional 27,200 shares in the last quarter. Finally, Acuitas Investments LLC grew its stake in Kodiak Sciences by 59.2% in the fourth quarter. Acuitas Investments LLC now owns 234,092 shares of the company’s stock valued at $712,000 after acquiring an additional 87,043 shares during the period. 89.06% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on KOD shares. Barclays upped their target price on Kodiak Sciences from $2.00 to $3.00 and gave the stock an “underweight” rating in a research report on Monday, April 1st. UBS Group upped their price objective on shares of Kodiak Sciences from $3.00 to $5.00 and gave the stock a “neutral” rating in a report on Thursday, April 4th. Three analysts have rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $5.50.

Kodiak Sciences Trading Up 3.1 %

Shares of NASDAQ:KOD traded up $0.09 during mid-day trading on Monday, hitting $2.96. 127,458 shares of the company traded hands, compared to its average volume of 622,321. The stock has a 50-day moving average price of $2.88 and a two-hundred day moving average price of $3.98. Kodiak Sciences Inc. has a 12-month low of $1.37 and a 12-month high of $7.77. The stock has a market cap of $155.49 million, a P/E ratio of -0.67 and a beta of 2.38.

Kodiak Sciences (NASDAQ:KOD) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.27. As a group, analysts expect that Kodiak Sciences Inc. will post -3.55 earnings per share for the current year.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.